Abstract
Over the last decade, metronomic chemotherapy has been increasingly considered as an attractive strategy for treating cancer in a variety of settings. Beside pharmaco-economic considerations making metronomics a unique opportunity in low- or middle-income countries, revisiting dosing schedules using continuous low doses of cytotoxics should theoretically permit to reduce the incidence of treatment-related toxicities, while offering unexpected novel mechanisms of actions such as antiangiogenic or immuno-stimulating properties. Consequently, a number of clinical trials sought to evaluate to what extent switching to metronomic schedules could actually impact indeed on the efficacy/toxicity balance of a variety of anticancer drugs in both adults and pediatric oncology. Vinorelbine is a vinca-alcaloïd that remains the backbone of several regimens to treat patients with metastatic breast cancer or non-small cell lung cancer. Additionally, vinorelbine is widely used to treat a variety of solid tumors in children such as rhabdomyosarcomas and acute leukemia. The recent approval of an oral formulation of vinorelbine has open the way to developing alternative metronomic schedules with this drug. Consequently, a number of clinical trials investigating on metronomic vinorelbine have been performed over the last few years, with seemingly inconsistent results to date. Of note, all the studies published thus far were based upon empirical determination of the metronomic schedule, both in terms of doses, drug-free intervals and repartition of the administrations throughout time. Because the very concept of «low, repeated doses with little or no drug-free interval» covers numerous possible combinations, determining the optimal protocol using traditional under-powered empirical design looks like an unreachable goal. In this context, mathematical modeling offers invaluable in silico tools to help determining the optimal metronomic schedule among a variety of possibilities. This review covers the latest clinical trials investigating on metronomic vinorelbine and proposes alternative strategies for developing computational decision support to make metronomics a scientific-grounded strategy, rather than an empirical practice at the bedside. In particular, mathematical simulations using an original pharmacokinetics/pharmacodynamics constraint models provide clues for exploring new paths in the way metronomic vinorelbine could be scheduled in patients with lung cancer.
References
Caffo O, Dipasquale M, Murgia V, Veccia A, Galligioni E (2013) An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. Expert Opin Drug Metab Toxicol 9:1037–1051
Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C, Defachelles AS, André N, Corradini N, Schmitt C, Tabone MD, Blouin P, Sirvent N, Goma G, Geoerger B, Oberlin O (2012) Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma—a report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE). Eur J Cancer 48:2409–2416
Shukla N, Kobos R, Renaud T, Steinherz LJ, Steinherz PG (2014) Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. Pediatr Blood Cancer 61:431–435
Galano G, Caputo M, Tecce MF, Capasso A (2011) Efficacy and tolerability of vinorelbine in the cancer therapy. Curr Drug Saf 6:185–193
Faller BA, Pandit TN (2011) Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer. Clin Med Insights Oncol 5:131–144
Aapro MS, Conte P, González EE, Trillet-Lenoir V (2007) Oral vinorelbine: role in the management of metastatic breast cancer. Drugs 67:657–667
André N, Padovani L, Verschuur A (2010) Metronomic chemotherapy: back to the future. Drug News Perspect 23:143–151
Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U (2013) Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer 49:3387–3395
Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, Pavlidis N (2009) Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15:6454–6461
Pallis AG, Chandrinos V, Pavlakou G, Xenidis N, Varthalitis I, Vardakis N, Vamvakas L, Kontopodis E, Rovithi M, Georgoulias V (2011) A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. Cancer Chemother Pharmacol 67:1239–1245
Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, Capasso E, Leo L, Botti G, Caraglia M, Del Prete S (2010) Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer 10:301–306
Rajdev L, Negassa A, Dai Q, Goldberg G, Miller K, Sparano JA (2011) Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol 68:1119–1124
Saloustros E, Kalbakis K, Vardakis N, Kalykaki A, Milaki G, Rovithi M, Agelaki S, Saridaki Z, Georgoulias V, Mavroudis D (2011) Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. J BUON 16:215–218
Saridaki Z, Malamos N, Kourakos P, Polyzos A, Ardavanis A, Androulakis N, Kalbakis K, Vamvakas L, Georgoulias V, Mavroudis D (2012) A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 69:35–42
Addeo R, Sperlongano P, Montella L, Vincenzi B, Carraturo M, Iodice P, Russo P, Parlato C, Salzano A, Cennamo G, Lombardi A, Sperlongano R, Prete SD, Caraglia M (2012) Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol 70:603–609
Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N, Vardakis N, Rovithi M, Georgoulias V, Agelaki S (2013) A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. J Chemother 25:49–55
Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, Makatsoris T, Varthalitis I, Xanthakis I, Vassias A, Klouvas G, Boukovinas I, Fountzilas G, Syrigos KN, Kalofonos H, Samantas E (2013) Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 13:263
Cazzaniga ME, Torri V, Villa F, Giuntini N, Riva F, Zeppellini A, Cortinovis D, Bidoli P (2014) Efficacy and safety of the all-oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: the phase I-II VICTOR-1 study. Int J Breast Cancer 2014:769790
Mukherjee A, Majumder D (2008) Mathematical modelling for the assessment of the effect of drug application delays in metronomic chemotherapy of cancer due to physiological constraints. Biosystems 91:108–116
Panetta JC, Schaiquevich P, Santana VM, Stewart CF (2008) Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res 14:318–325
Faivre C, Barbolosi D, Pasquier E, André N (2013) A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens. Cancer Chemother Pharmacol 71:1013–1019
Rygaard K, Spang-Thomsen M (1997) Quantitation and gompertzian analysis of tumor growth. Breast Cancer Res Treat 46:303–312
Kerbel RS (2009) Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast 8:S41–S47
Dimova I, Popivanov G, Djonov V (2014) Angiogenesis in cancer-general pathways and their therapeutic implications. J BUON 19:15–21
Meille C, Iliadis A, Barbolosi D, Frances N, Freyer G (2008) An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. J Pharmacokinet Pharmacodyn 35:619–633
Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713–4721
Meille C, Gentet JC, Barbolosi D, André N, Doz F, Iliadis A (2008) New adaptive method for phase I trials in oncology. Clin Pharmacol Ther 83:873–881
Marouani H, Woloch C, Benay S, Frances N, Iliadis A (2012) Progress in strategies for dosage regimen individualization. Curr Top Med Chem 12:1669–1677
Tsimberidou AM, Eggermont AM, Schilsky RL (2014) Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 61–9
Agur Z, Elishmereni M, Kheifetz Y (2014) Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration. Wiley Interdiscip Rev Syst Biol Med 6: 239–53
Lee JJ, Chu CT (2012) Bayesian clinical trials in action. Stat Med 31:2955–2972
Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Duffaud F, Digue L, Tranchand B, Monjanel-Mouterde S, Guillet P, Nicoara A, Baciuchka M, Bagarry-Liegey D, Lacarelle B, Noble A, Durand A, Favre R (2006) Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities. Ther Drug Monit 28:212–218
Chen CS, Doloff JC, Waxman DJ (2014) Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 16:84–96
André N, Carré M, Pasquier E (2014) Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 11:413–431
Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7:455–465
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barbolosi, D., Ciccolini, J., Meille, C. et al. Metronomics chemotherapy: time for computational decision support. Cancer Chemother Pharmacol 74, 647–652 (2014). https://doi.org/10.1007/s00280-014-2546-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-014-2546-1